Evaxion A/S (EVAX)

CIK 0001828253 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
—
Statements
Consolidated Statements of Comprehensive Loss
—
Consolidated Statements of Financial Position
—
Consolidated Statements of Changes In Equity (deficit)
—
Consolidated Statements of Cash Flows
—
Notes
Basic and Diluted Loss Per Share
—
Borrowings
—
Capital Structure and Financial Matters
—
Cash and Cash Equivalents
—
Commitments and Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Employees and Employee-related Costs
—
Events After The Reporting Period
—
Fees To Auditors
—
Financial Income and Expenses
—
Financial Instruments and Risk Management
—
General Company Information
—
Income Taxes
—
Insider Trading Arrangements
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Leases
—
Liquidity and Going Concern Assessment
—
Note 1
—
Note 10
—
Note 11
—
Note 12
—
Note 13
—
Note 14
—
Note 15
—
Note 16
—
Note 17
—
Note 18
—
Note 19
—
Note 2
—
Note 20
—
Note 21
—
Note 22
—
Note 23
—
Note 24
—
Note 25
—
Note 3
—
Note 4
—
Note 5
—
Note 6
—
Note 7
—
Note 8
—
Note 9
—
Operating Activities
—
Other Payables
—
Prepayments and Other Receivables
—
Property and Equipment, Net
—
Provisions
—
Related Party Transactions
—
Revenue
—
Share-based Payments
—
Significant Accounting Judgements, Estimates, and Assumptions
—
Summary of Accounting Policies
—